Skip to main content

Lixte Biotechnology Holdings, Inc. (LIXT)

NASDAQ: LIXT · Delayed Price · USD
2.11
+0.01 (0.48%)
After-hours:Sep 23, 2021 6:10 PM EDT
2.10
0.03 (1.45%)
At close: Sep 23, 4:00 PM
Market Cap28.59M
Revenue (ttm)n/a
Net Income (ttm)-5.97M
Shares Out13.75M
EPS (ttm)-0.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,398
Open2.09
Previous Close2.07
Day's Range2.06 - 2.11
52-Week Range1.97 - 7.19
Beta-1.35
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About LIXT

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically ac...

IndustryBiotechnology
Founded2005
Employees3
Stock ExchangeNASDAQ
Ticker SymbolLIXT
Full Company Profile

Financial Performance

Financial Statements

News

Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Fe...

A series of recent pre - clinical reports demonstrat e s LB-100's effectiveness in various non - neoplastic diseases that may benefit from PP2A inhibition

1 month ago - GlobeNewsWire

Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now

Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:IBIOOTLK
1 month ago - PennyStocks

Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer

Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) has announced that its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard...

1 month ago - Benzinga

LIXTE BIOTECHNOLOGY'S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPO...

A Pre-Clinical Study Reports that LB -100 Potentiates Standard Therapy f or Small Cell Lung Cancer Providing a Strong Rational e f or a Clinical Trial o f LB -100 i n Small Cell Lung Cancer Recently Ini...

1 month ago - GlobeNewsWire

LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STI...

Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer t...

2 months ago - GlobeNewsWire

Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy ...

Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State...

2 months ago - GlobeNewsWire

Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on Ju...

Presentation to highlight Company's current clinical stud y of lead compound LB-100 for Small Cell Lung Cancer

2 months ago - GlobeNewsWire

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of ...

EAST SETAUKET, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cance...

3 months ago - GlobeNewsWire

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS

EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq : LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as a...

4 months ago - GlobeNewsWire

Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Co...

Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments

4 months ago - GlobeNewsWire

Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacolog...

5 months ago - GlobeNewsWire

Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Confe...

EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in can...

6 months ago - GlobeNewsWire

WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, I...

LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology ...

6 months ago - Business Wire

WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings...

JERSEY CITY, N.J., March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a Registered Direct Offering...

6 months ago - PRNewsWire

Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer t...

6 months ago - GlobeNewsWire

Why Morphic, Athenex, Lixte Biotech Are Moving Today

Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma ...

Other symbols:ATNXMORF
6 months ago - Benzinga

Lixte Biotechnology Announces $4.19 Million Registered Direct Offering

East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer...

6 months ago - GlobeNewsWire

LIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast Off

Lixte Biotechnology (LIXT) stock is heading higher on Friday with heavy trading of shares despite a lack of news concerning the company. The post LIXT Stock: 8 Things to Know About Lixte Biotechnology A...

6 months ago - InvestorPlace

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sci...

EAST SETAUKET, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc...

6 months ago - GlobeNewsWire

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte's Lead Compound LB-100 to Treat Sma...

EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc...

8 months ago - GlobeNewsWire